PLUS THERAPEUTICS, Inc. Common Stock (PSTV) Stock Price

PSTVStock

$1.69−74.72%52W

Market Cap$11.63M

P/E—

PEG Ratio2.45

Div yield—

Beta1.54

PSTV Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-62.15%

Price vs S&P 500 (4W)-27.55%

PEG Ratio2.45

VGM Score45.73

Book Value / Share (Quarterly)$1.74

P/TBV (Annual)19.22x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-68.25%

Cash Flow / Share (Quarterly)$-3.17

Price vs S&P 500 (YTD)-96.52%

Gross Margin (TTM)74.77%

Net Profit Margin (TTM)-404.27%

EPS (TTM)$-2.50

10-Day Avg Trading Volume0.11M

EPS Excl Extra (TTM)$-6.18

Revenue Growth (5Y)-48.87%

EPS (Annual)$-7.19

ROI (Annual)-471.68%

Gross Margin (Annual)64.36%

Net Profit Margin (5Y Avg)-407.87%

Cash / Share (Quarterly)$2.20

Revenue Growth QoQ (YoY)1598.63%

ROA (Last FY)-137.13%

Revenue Growth TTM (YoY)5038.36%

EBITD / Share (TTM)$-5.59

ROE (5Y Avg)-203.08%

Operating Margin (TTM)-400.77%

Cash Flow / Share (Annual)$-3.76

P/B Ratio2.23x

P/B Ratio (Quarterly)2.33x

Net Income / Employee (Annual)$-799,500

EV / Revenue (TTM)4.69x

Net Interest Coverage (TTM)-2.66x

ROA (TTM)-73.13%

EPS Growth QoQ (YoY)65.01%

EPS Incl Extra (Annual)$-7.19

Current Ratio (Annual)1.23x

Quick Ratio (Quarterly)2.12x

3-Month Avg Trading Volume0.13M

52-Week Price Return-74.72%

Revenue / Employee (TTM)$220,647,100,000

Tangible BV / Share (Quarterly)$1.70

P/S Ratio (Annual)5.11x

Asset Turnover (Annual)0.32x

52-Week High$18.88

Operating Margin (5Y Avg)-410.06%

EPS Excl Extra (Annual)$-7.19

CapEx CAGR (5Y)-19.40%

Tangible BV CAGR (5Y)26.16%

26-Week Price Return-52.25%

Quick Ratio (Annual)1.12x

13-Week Price Return-55.50%

Total Debt / Equity (Annual)0.19x

Current Ratio (Quarterly)2.27x

Enterprise Value$24.28M

Revenue / Share Growth (5Y)-84.61%

Asset Turnover (TTM)0.21x

Book Value / Share Growth (5Y)-72.05%

Revenue / Employee (Annual)$186,200

Inventory Turnover (Annual)1.44x

Pretax Margin (Annual)-429.43%

Cash / Share (Annual)$1.55

3-Month Return Std Dev88.39%

Gross Margin (5Y Avg)66.98%

Net Income / Employee (TTM)$-892,000,000,000

ROE (Last FY)-560.21%

Net Interest Coverage (Annual)-35.01x

EPS Basic Excl Extra (Annual)$-7.19

P/FCF (TTM)27.46x

Receivables Turnover (TTM)45.74x

Total Debt / Equity (Quarterly)0.06x

EPS Incl Extra (TTM)$-6.18

Receivables Turnover (Annual)0.51x

ROI (TTM)-164.61%

P/S Ratio (TTM)1.97x

Pretax Margin (5Y Avg)-407.87%

Revenue / Share (Annual)$1.68

Tangible BV / Share (Annual)$0.66

Free OCF CAGR (5Y)-16.92%

Price vs S&P 500 (52W)-77.67%

EPS Growth TTM (YoY)53.56%

Year-to-Date Return-86.73%

5-Day Price Return-6.08%

EPS Normalized (Annual)$-7.19

ROA (5Y Avg)-53.03%

Net Profit Margin (Annual)-429.43%

Month-to-Date Return-16.26%

Cash Flow / Share (TTM)$-5.64

EBITD / Share (Annual)$-4.77

Operating Margin (Annual)-293.46%

LT Debt / Equity (Annual)58.74x

ROI (5Y Avg)-121.85%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-6.18

P/TBV (Quarterly)2.39x

P/B Ratio (Annual)17.62x

Inventory Turnover (TTM)0.74x

Pretax Margin (TTM)-404.27%

Book Value / Share (Annual)$0.72

Price vs S&P 500 (13W)-58.18%

Beta1.54x

Revenue / Share (TTM)$1.46

ROE (TTM)-83.36%

52-Week Low$1.49

vGradeC

gGradeB

mGradeD

vgmGradeC

PSTV Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q1 2026	May 15, 2026	-$0.87	-$1.05	-20.69%(-$0.18)
Q4 2025	Mar 12, 2026	-$0.92	$0.00	+100.00%(+$0.92)
Q3 2025	Oct 30, 2025	-$0.88	-$1.00	-14.29%(-$0.13)
Q2 2025	Aug 14, 2025	-$3.25	-$0.16	+95.00%(+$3.09)

PSTV Analyst Recommendations

Apr 2026

May 2026

Jun 2026

Jul 2026

4.00

4.10

Industry Peers — Surgical & Medical Instruments(142)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth (5Y)	Gross Margin (TTM)	Operating Margin (TTM)	Price
PSTVPLUS THERAPEUTICS, Inc. Common Stock	C	B	D	2.0x	-48.9%	74.8%	-400.8%	$1.69
SYKStryker Corporation	C	B	C	4.4x	11.8%	65.3%	21.3%	$294.66
MMM3M Company	C	D	B	3.4x	-5.0%	39.4%	18.4%	$164.75
BSXBoston Scientific Corp.	C	B	C	3.1x	15.2%	69.5%	19.8%	$44.39
BDXBecton, Dickinson and Co.	B	D	A	2.5x	6.3%	46.7%	9.6%	$191.75
MDLNMedline Inc. Class A common stock	C	D	C	1.6x	—	26.2%	6.0%	$35.96
RMDResMed Inc.	C	C	B	5.9x	12.1%	61.1%	33.4%	$238.97
DXCMDexCom, Inc.	C	B	B	6.5x	19.3%	64.3%	22.9%	$86.04
WSTWest Pharmaceutical Services, Inc.	D	C	A	8.5x	7.4%	36.8%	20.4%	$384.02
SOLVSolventum Corporation	C	C	B	1.8x	—	54.8%	23.9%	$85.81
BAXBaxter International Inc.	B	D	B	1.1x	-0.8%	30.7%	-2.3%	$25.28
PENPenumbra, Inc.	F	C	B	8.4x	20.2%	67.8%	12.4%	$320.86
GMEDGLOBUS MEDICAL INC	B	B	B	3.3x	30.1%	68.5%	20.6%	$76.71
PODDInsulet Corporation	C	A	C	3.2x	24.5%	71.1%	16.9%	$141.10
GKOSGlaukos Corporation	F	A	B	15.9x	17.7%	79.1%	-31.6%	$164.84
TFXTeleflex Incorporated	B	F	B	2.1x	-4.7%	53.8%	-11.7%	$130.43
HAEHaemonetics Corporation	C	C	A	4.0x	8.9%	59.1%	11.9%	$118.28
MMSIMerit Medical Systems Inc	C	B	B	3.4x	9.5%	49.5%	12.8%	$89.20
STVNStevanato Group S.p.A.	D	C	C	3.7x	12.4%	29.9%	16.4%	$18.90
MMEDMiniMed Group, Inc. Common Stock	—	—	B	—	—	—	—	$17.49
HTFLHeartflow, Inc. Common Stock	F	A	A	19.8x	—	80.1%	-40.8%	$48.29
ICUIICU Medical Inc	C	D	B	1.9x	11.9%	39.1%	3.5%	$162.99
IRTCiRhythm Holdings, Inc. Common Stock	D	B	C	4.3x	23.0%	71.5%	-3.0%	$108.66
PLSEPulse Biosciences, Inc Common Stock (DE)	F	—	A	2725.9x	—	0.3%	-7007.8%	$44.43
ATRCAtriCure, Inc.	D	B	A	5.0x	20.9%	76.3%	2.3%	$56.07
UFPTUFP Technologies Inc	C	B	A	3.6x	27.4%	28.5%	15.3%	$291.67
INSPInspire Medical Systems, Inc.	B	B	B	2.2x	51.2%	86.1%	6.0%	$68.79
LMATLeMaitre Vascular, Inc.	C	B	C	7.0x	14.0%	72.9%	29.5%	$80.82
NVCRNovoCure Limited Ordinary Shares	D	C	C	2.3x	5.8%	76.1%	-22.1%	$14.07
KMTSKestra Medical Technologies, Ltd. Common Stock	F	A	B	15.2x	—	53.9%	-140.4%	$27.24
ATECAlphatec Holdings, Inc.	D	B	C	2.0x	39.5%	70.8%	-7.5%	$10.46
DRTSAlpha Tau Medical Ltd. Ordinary Shares	—	—	B	—	—	—	—	$12.29
TNDMTandem Diabetes Care, Inc.	D	C	C	1.1x	15.3%	56.0%	-4.4%	$16.24
IRMDiRadimed Corporation	D	B	B	13.1x	21.4%	75.9%	31.9%	$88.27
AORTArtivion, Inc.	C	C	C	2.3x	11.8%	64.4%	2.9%	$21.78
IARTIntegra LifeSciences Holdings	B	F	C	0.6x	3.6%	57.2%	4.0%	$13.21
PRCTPROCEPT BioRobotics Corporation Common Stock	C	A	D	3.0x	109.0%	64.2%	-33.9%	$17.57
BVSBioventus Inc. Class A Common Stock	B	C	A	1.9x	12.1%	68.7%	10.0%	$13.30
BBNXBeta Bionics, Inc. Common Stock	D	A	C	7.4x	—	58.3%	-69.8%	$16.35
SIBNSI-BONE, Inc. Common Stock	D	B	B	4.1x	22.3%	79.5%	-8.3%	$19.68
SGPSpyGlass Pharma, Inc. Common Stock	—	—	B	—	—	—	—	$24.00
MDXGMiMedx Group, Inc	C	D	C	1.8x	11.0%	78.8%	2.5%	$4.43
KIDSOrthoPediatrics Corp. Common Stock	C	B	B	2.3x	27.2%	73.7%	-11.9%	$21.95
TCMDTactile Systems Technology, Inc.	B	B	B	1.5x	12.0%	51.9%	10.0%	$22.52
SSIISS Innovations International Inc. Common Stock	F	A	D	9.7x	—	47.6%	-16.2%	$2.53
DCTHDelcath Systems Inc	D	C	B	5.1x	120.1%	87.0%	-1.9%	$14.08
ANGOAngioDynamics, Inc.	C	D	C	1.5x	1.9%	55.6%	-11.2%	$11.24
BWAYBrainsway Ltd. American Depositary Shares	D	B	B	9.5x	12.2%	74.9%	5.8%	$11.44
SGHTSight Sciences, Inc. Common Stock	D	B	A	5.5x	22.9%	88.4%	-33.4%	$8.28
CERSCerus Corp	D	C	C	1.8x	15.4%	57.2%	-0.7%	$2.18
NPCENeuropace, Inc. Common Stock	D	C	C	4.3x	19.4%	79.6%	-15.3%	$12.24

About PLUS THERAPEUTICS, Inc. Common Stock

Plus Therapeutics is a clinical-stage pharmaceutical company developing treatments for CNS cancers, including recurrent glioblastoma and leptomeningeal metastases. Its lead candidate, rhenium-186 obisbemeda, is a targeted radiotherapeutic designed for cancers with limited treatment options, including pediatric brain cancers.